{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:28:50Z","timestamp":1784762930021,"version":"3.55.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Meloxicam is an enolate nonsteroidal anti\u2010inflammatory agent. This trial investigated the pharmacokinetics, safety, and bioequivalence of single oral doses of Aomei meloxicam (15\u00a0mg) and Mobic meloxicam (15\u00a0mg) in healthy volunteers under fasting and fed conditions. A single\u2010site, single\u2010dose, randomized, open, 2\u2010period, 2\u2010sequence, crossover bioequivalence study was performed: 24 healthy volunteers were enrolled in each of the fasting and fed arms. Each HV was randomly assigned to receive the Aomei drug (test) in one period and the Mobic drug (reference) in the other period. The concentration of meloxicam in plasma was detected using liquid chromatography\u2013tandem mass spectrometry. The primary pharmacokinetic parameters were calculated using a noncompartmental model. In the fasting arm, the 90% confidence interval of the geometric mean ratios of maximum plasma concentration, area under the concentration\u2010time curve from time 0 to the last measurable plasma concentration, and area under the concentration\u2010time curve from time 0 to infinity between the test and reference products were 99.5% to 111.7%, 101.2% to 106.8%, and 101.8% to 108.3%, respectively. In the fed arm, the 3 parameters were 94.1% to 102.4%, 97.6% to 103.0%, and 97.5% to 103.7%, respectively. These parameters were in the range of 80% to 125%, and the 2 products were considered bioequivalent in both the fasting and fed states and were well tolerated. The severity of all adverse events was mild. Aomei meloxicam tablets and Mobic meloxicam tablets were bioequivalent in healthy Chinese volunteers.<\/jats:p>","DOI":"10.1002\/cpdd.965","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T11:30:05Z","timestamp":1623929405000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of Meloxicam Tablets in Healthy Chinese Adults in the Fasting and Fed States: A Single\u2010Site, Single\u2010Dose, Randomized, Open, 2\u2010Period, 2\u2010Sequence, Crossover Bioequivalence Study"],"prefix":"10.1002","volume":"11","author":[{"given":"Jin","family":"Yu","sequence":"first","affiliation":[{"name":"Zhejiang Chinese Medical University  Hangzhou China"},{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Wang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Lin","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hao","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Fang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhao","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjia","family":"Tong","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkai","family":"Si","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Ye","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[{"name":"Quzhou People's Hospital  Quzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Departments of TCM Gynecology Zhejiang Provincial People's Hospital  Wenzhou China"},{"name":"Clinical Research Institute Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center Zhejiang Provincial People's Hospital People's Hospital of Hangzhou Medical College  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"362:k3015","article-title":"Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance","author":"Allen A","year":"2018","journal-title":"BMJ"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479018794159"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936020-00003"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651030-00007"},{"issue":"2","key":"e_1_2_8_6_1","first-page":"199","article-title":"Bioequivalence studies of two brands of meloxicam tablets in healthy Pakistani volunteers","volume":"22","author":"Hasan S","year":"2009","journal-title":"Pak J Pharm Sci"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00198310"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/004982598239704"},{"issue":"11","key":"e_1_2_8_9_1","first-page":"1206","article-title":"Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects","volume":"23","author":"Schmid J","year":"1995","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"e_1_2_8_10_1","first-page":"253","article-title":"Clinical pharmacokinetics of meloxicam","volume":"47","author":"T\u00fcrck D","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.937"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.946"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)02111-6"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)02110-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.58"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.suppl_1.17"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201781"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S39024"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.4238\/2014.February.13.1"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12859"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199509050-00004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1337979"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.446"},{"issue":"5","key":"e_1_2_8_24_1","first-page":"264","article-title":"Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects","volume":"57","author":"Gschwend M","year":"2007","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"e_1_2_8_25_1","first-page":"115","article-title":"Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects","volume":"68","author":"Ahmad M","year":"2011","journal-title":"Acta Pol Pharm"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.965","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:39:37Z","timestamp":1693229977000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/cpdd.965"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.965","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}